M Obón-Santacana1, N Slimani2, L Lujan-Barroso1, N Travier1, G Hallmans3, H Freisling2, P Ferrari4, M C Boutron-Ruault5, A Racine5, F Clavel5, C Saieva6, V Pala7, R Tumino8, A Mattiello9, P Vineis10, M Argüelles11, E Ardanaz12, P Amiano13, C Navarro14, M J Sánchez15, E Molina Montes15, T Key16, K-T Khaw17, N Wareham18, P H Peeters19, A Trichopoulou20, C Bamia21, D Trichopoulos22, H Boeing23, R Kaaks24, V Katzke24, W Ye25, M Sund26, U Ericson27, E Wirfält28, K Overvad29, A Tjønneland30, A Olsen30, G Skeie31, L A Åsli31, E Weiderpass32, E Riboli33, H B Bueno-de-Mesquita34, E J Duell35. 1. Unit of Nutrition, Environment and Cancer, Cancer Epidemiology Research Program, Catalan Institute of Oncology (ICO-IDIBELL), Barcelona, Spain. 2. Dietary Exposure Assessment Group, International Agency for Research on Cancer, Lyon, France. 3. Department of Public Health and Clinical Medicine, Nutritional Research, Umeå University, Umeå, Sweden. 4. Nutritional Epidemiology Group, International Agency for Research on Cancer, Lyon. 5. Inserm, Centre for research in Epidemiology and Population Health (CESP), Nutrition, Hormones and Women's Health team, Villejuif; Paris-Sud University, Villejuif; Institut Gustave Roussy, Villejuif, France. 6. Molecular and Nutritional Epidemiology Unit, Cancer Research and Prevention Institute-ISPO, Florence. 7. Department of Preventive and Predictive Medicine, Nutritional Epidemiology Unit, Fondazione IRCSS Istituto Nazionale dei Tumori, Milan. 8. Cancer Registry and Histopathology Unit, 'Civile-M.P. Arezzo' Hospital, ASP Ragusa. 9. Dipartimento di Medicina Clinica e Chirurgia, Federico II University of Naples, Naples, Italy. 10. Centre for Environment and Health, School of Public Health, Imperial College London, London, UK; Human Genetics Foundation (HuGeF), Torino, Italy. 11. Public Health and Participation Directorate, Health and Health Care Services Council, Asturias. 12. Navarre Public Health Institute, Pamplona; CIBER Epidemiology and Public Health CIBERESP. 13. CIBER Epidemiology and Public Health CIBERESP; Department of Health of the Regional Government of the Basque Country, Public Health Division of Gipuzkoa, BIODonostia Research Institute, San Sebastian. 14. CIBER Epidemiology and Public Health CIBERESP; Department of Epidemiology, Murcia Regional Health Council, Murcia; Department of Health and Social Sciences, University of Murcia, Murcia. 15. CIBER Epidemiology and Public Health CIBERESP; Andalusian School of Public Health, Granada, Spain. 16. Cancer Epidemiology Unit, Nuffield Department of Clinical Medicine, University of Oxford, Oxford. 17. Department Public Health and Primary Care, University of Cambridge, Cambridge. 18. MRC Epidemiology Unit, Institute of Metabolic Science, Addenbrooke's Hospital, Cambridge, UK. 19. Julius Center for Health Sciences and Primary Care, University Medical Center, Utrecht, The Netherlands; Department of Epidemiology & Biostatistics, School of Public Health, Imperial College London, London, UK. 20. WHO Collaborating Center for Food and Nutrition Policies, Department of Hygiene, Epidemiology and Medical Statistics, University of Athens Medical School, Athens; Hellenic Health Foundation, Athens, Greece. 21. WHO Collaborating Center for Food and Nutrition Policies, Department of Hygiene, Epidemiology and Medical Statistics, University of Athens Medical School, Athens. 22. Hellenic Health Foundation, Athens, Greece; Department of Epidemiology, Harvard School of Public Health, Boston, USA; Bureau of Epidemiologic Research, Academy of Athens, Athens, Greece. 23. Department of Epidemiology, German Institute of Human Nutrition, Potsdam-Rehbruecke, Nuthetal. 24. Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany. 25. Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm; The Medical Biobank at Umeå University, Umeå. 26. Departments of Surgical and Perioperative Sciences, Surgery and Public Health, Clinical Medicine, Nutrition Research, Umeå University, Umeå. 27. Department of Clinical Sciences, Diabetes and Cardiovascular Disease, Genetic Epidemiology, Lund University, Clinical Research Centre, Malmö. 28. Department of Clinical Sciences, Nutrition Epidemiology, Lund University, Malmö, Sweden. 29. Department of Epidemiology and Social Medicine, Department of Public Health, Aarhus University, Aarhus. 30. Danish Cancer Society Research Center, Institute of Cancer Epidemiology, Diet, Cancer and Health, Copenhagen, Denmark. 31. Department of Community Medicine, Faculty of Health Sciences, University of Tromsø, Tromsø, Norway. 32. Department of Community Medicine, Faculty of Health Sciences, University of Tromsø, Tromsø, Norway; Department of Medical Epidemiology and Biostatistics, Karolinska Institute, Stockholm, Sweden; Public Health Association, Public Health Research Center, Helsinki, Finland. 33. Department of Epidemiology & Biostatistics, School of Public Health, Imperial College London, London, UK. 34. National Institute for Public Health and the Enviroment (RIVM), Bilthoven; Department of Gastroenterology and Hepatology, University Medical Centre, Utretcht, The Netherlands. 35. Unit of Nutrition, Environment and Cancer, Cancer Epidemiology Research Program, Catalan Institute of Oncology (ICO-IDIBELL), Barcelona, Spain. Electronic address: eduell@iconcologia.net.
Abstract
BACKGROUND: In 1994, acrylamide (AA) was classified as a probable human carcinogen by the International Agency for Research on Cancer. In 2002, AA was discovered at relatively high concentrations in some starchy, plant-based foods cooked at high temperatures. PATIENTS AND METHODS: A prospective analysis was conducted to evaluate the association between the dietary intake of AA and ductal adenocarcinoma of the exocrine pancreatic cancer (PC) risk in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort using Cox regression modeling. EPIC includes >500,000 men and women aged 35-75 at enrollment from 10 European countries. AA intake was estimated for each participant by combining questionnaire-based food consumption data with a harmonized AA database derived from the EU monitoring database of AA levels in foods, and evaluated in quintiles and continuously. RESULTS: After a mean follow-up of 11 years, 865 first incident adenocarcinomas of the exocrine pancreas were observed and included in the present analysis. At baseline, the mean dietary AA intake in EPIC was 26.22 µg/day. No overall association was found between continuous or quintiles of dietary AA intake and PC risk in EPIC (HR:0.95, 95%CI:0.89-1.01 per 10 µg/day). There was no effect measure modification by smoking status, sex, diabetes, alcohol intake or geographic region. However, there was an inverse association (HR: 0.73, 95% CI: 0.61-0.88 per 10 µg/day) between AA intake and PC risk in obese persons as defined using the body mass index (BMI, ≥ 30 kg/m(2)), but not when body fatness was defined using waist and hip circumference or their ratio. CONCLUSIONS: Dietary intake of AA was not associated with an increased risk of PC in the EPIC cohort.
BACKGROUND: In 1994, acrylamide (AA) was classified as a probable human carcinogen by the International Agency for Research on Cancer. In 2002, AA was discovered at relatively high concentrations in some starchy, plant-based foods cooked at high temperatures. PATIENTS AND METHODS: A prospective analysis was conducted to evaluate the association between the dietary intake of AA and ductal adenocarcinoma of the exocrine pancreatic cancer (PC) risk in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort using Cox regression modeling. EPIC includes >500,000 men and women aged 35-75 at enrollment from 10 European countries. AA intake was estimated for each participant by combining questionnaire-based food consumption data with a harmonized AA database derived from the EU monitoring database of AA levels in foods, and evaluated in quintiles and continuously. RESULTS: After a mean follow-up of 11 years, 865 first incident adenocarcinomas of the exocrine pancreas were observed and included in the present analysis. At baseline, the mean dietary AA intake in EPIC was 26.22 µg/day. No overall association was found between continuous or quintiles of dietary AA intake and PC risk in EPIC (HR:0.95, 95%CI:0.89-1.01 per 10 µg/day). There was no effect measure modification by smoking status, sex, diabetes, alcohol intake or geographic region. However, there was an inverse association (HR: 0.73, 95% CI: 0.61-0.88 per 10 µg/day) between AA intake and PC risk in obese persons as defined using the body mass index (BMI, ≥ 30 kg/m(2)), but not when body fatness was defined using waist and hip circumference or their ratio. CONCLUSIONS: Dietary intake of AA was not associated with an increased risk of PC in the EPIC cohort.
Entities:
Keywords:
acrylamide; cohort; nutrition; pancreatic cancer
Authors: Mireia Obón-Santacana; Leila Lujan-Barroso; Heinz Freisling; Claire Cadeau; Guy Fagherazzi; Marie-Christine Boutron-Ruault; Rudolf Kaaks; Renée T Fortner; Heiner Boeing; J Ramón Quirós; Esther Molina-Montes; Saioa Chamosa; José María Huerta Castaño; Eva Ardanaz; Kay-Tee Khaw; Nick Wareham; Tim Key; Antonia Trichopoulou; Pagona Lagiou; Androniki Naska; Domenico Palli; Sara Grioni; Rosario Tumino; Paolo Vineis; Maria Santucci De Magistris; H B Bueno-de-Mesquita; Petra H Peeters; Maria Wennberg; Ingvar A Bergdahl; Hubert Vesper; Elio Riboli; Eric J Duell Journal: Eur J Nutr Date: 2016-02-05 Impact factor: 5.614
Authors: C Pelucchi; V Rosato; P M Bracci; D Li; R E Neale; E Lucenteforte; D Serraino; K E Anderson; E Fontham; E A Holly; M M Hassan; J Polesel; C Bosetti; L Strayer; J Su; P Boffetta; E J Duell; C La Vecchia Journal: Ann Oncol Date: 2017-02-01 Impact factor: 32.976
Authors: Clara Amalie Gade Timmermann; Signe Sonne Mølck; Manik Kadawathagedara; Anne Ahrendt Bjerregaard; Margareta Törnqvist; Anne Lise Brantsæter; Marie Pedersen Journal: Toxics Date: 2021-06-30
Authors: M Obón-Santacana; R Kaaks; N Slimani; L Lujan-Barroso; H Freisling; P Ferrari; L Dossus; N Chabbert-Buffet; L Baglietto; R T Fortner; H Boeing; A Tjønneland; A Olsen; K Overvad; V Menéndez; E Molina-Montes; N Larrañaga; M-D Chirlaque; E Ardanaz; K-T Khaw; N Wareham; R C Travis; Y Lu; M A Merritt; A Trichopoulou; V Benetou; D Trichopoulos; C Saieva; S Sieri; R Tumino; C Sacerdote; R Galasso; H B Bueno-de-Mesquita; E Wirfält; U Ericson; A Idahl; N Ohlson; G Skeie; I T Gram; E Weiderpass; N C Onland-Moret; E Riboli; E J Duell Journal: Br J Cancer Date: 2014-06-17 Impact factor: 7.640
Authors: Mireia Obón-Santacana; Petra H M Peeters; Heinz Freisling; Laure Dossus; Françoise Clavel-Chapelon; Laura Baglietto; Helena Schock; Renée T Fortner; Heiner Boeing; Anne Tjønneland; Anja Olsen; Kim Overvad; Virginia Menéndez; Maria-José Sanchez; Nerea Larrañaga; José María Huerta Castaño; Aurelio Barricarte; Kay-Tee Khaw; Nick Wareham; Ruth C Travis; Melissa A Merritt; Antonia Trichopoulou; Dimitrios Trichopoulos; Philippos Orfanos; Giovanna Masala; Sabina Sieri; Rosario Tumino; Paolo Vineis; Amalia Mattiello; H B Bueno-de-Mesquita; N Charlotte Onland-Moret; Elisabeth Wirfält; Tanja Stocks; Annika Idahl; Eva Lundin; Guri Skeie; Inger T Gram; Elisabete Weiderpass; Elio Riboli; Eric J Duell Journal: Cancer Epidemiol Biomarkers Prev Date: 2014-10-09 Impact factor: 4.254